Research Funding Opportunities
Proposed research areas for 2014/15 EME commissioned calls - updated 1 July 2015
Research in the following broad areas is likely to be commissioned during the next year, although the titles and timings may be subject to change. The individual commissioning briefs, which will be published when the calls open, will define the details of the calls.
Use of cell therapies: anticipated opening date October 2015
Delirium: anticipated opening date TBC
Graft vs host disease: anticipated opening date TBC
EME funding opportunity 15/75 - Mechanisms of action of health interventions
Proposals are sought for translational research into the underlying mechanisms of action of clinical and public health interventions. Studies must utilise patients or samples from current or completed NIHR-funded or NIHR-managed studies in any setting. Proposals will be accepted across a wide range of interventions, including behavioural, pharmaceutical, psychological, surgical and public health interventions. The research should be relevant to the intervention and outcomes proposed by the original study and add significantly to the scientific understanding of the mechanisms of action of the intervention.
The proposed research may involve the analysis or reanalysis of previously stored specimens or data, or the collection of new specimens or new data for additional analysis, provided it is obtained from study participants. Discovery of new biomarkers is not within the remit of the EME Programme.
Applicants will need to make a strong case for how a better understanding of the mechanisms of action will potentially contribute to the future use or development of the technology, future wealth creation and for the ultimate benefit of individual patients’ or the wider NHS.
Further details of the commissioning brief are available to download, along with the guidance notes. The deadline for applications is 1pm on 10 November 2015. There is a webinar on 31 July 2015 from 11:00 to 11:45 to support the application process; click here to register.
EME funding opportunity 15/74 - Novel diagnostics and treatments for irritable bowel syndrome
A call has been made for proposals focussed on the diagnosis or treatment of irritable bowel syndrome. Applicants are encouraged to include a hypothesis-driven mechanistic element embedded within the main efficacy study to help better understand the mechanisms of the disease process or the proposed intervention are particularly encouraged. In the light of recent calls, applications for probiotics and faecal transplant therapies will not be favoured. Applications may investigate novel or repurposed interventions and technologies.
Further details of the commissioning brief are available to download, along with the guidance notes. The deadline for applications is 1pm on 10 November 2015..There is a webinar on 01 September 2015 from 12:00 to 12:45 to support the application process; click here to register.
EME funding opportunity 15/73 - Markers of early treatment response in non-cancerous conditions
A call has been made for translational research proposals into the early use of markers to assess and predict the further response to treatment of patients with non-cancerous conditions. This will contribute to the development of a personalised medicine approach to healthcare and help inform patient management decisions by enabling stratification of patients following initiation of treatment. Applications must concentrate on determining the clinical efficacy of the marker early in treatment. Applications to this call could focus on either the test or the use of a test to change the care pathway of patients.
Further details of the commissioning brief are available to download, along with the the guidance notes. The deadline for applications is 1pm on 10 November 2015. There is a webinar on 27 July 2015 from 13:15 to 14:00 to support the application process; click here to register.
Reminder: Funding deadlines approaching
Please note the Pancreatic Cancer Action Early Diagnosis Challenge Award deadline is fast approaching (6 July 2015), along with the deadline for the MRC Biochemical Catalyst: Developmental Pathway Funding Scheme (28 July). Further details of these opportunities are listed further down this page. The next EME researcher-led funding opportunity will open on 2 July 2015.
Proposed research areas for 2015 HTA commissioned calls - updated 18 May 2015
The HTA Programme is considering the following topic areas for future commissioned research. Please note that not all of these topics will ultimately be advertised, but if they are it is likely to be within the next 6 to 12 months. Please also note that topic areas and timings are subject to change. The individual commissioning briefs, which will be published when the call opens, will define the details of the call.
Biomarker-guided antibiotic duration
In patients with major bleeding, is a liberal treatment strategy with early fibrinogen concentrate, or fibrinogen containing plasma products, more effective than a more restrictive strategy
Treatment for people in remission from mild to moderate ulcerative colitis (UC)
The clinical and cost effectiveness of intravenous zoledronic acid in patients with osteoporosis due to alcoholic liver disease
Management of gastroschisis
HTA researcher-led funding opportunities - updated 18 May 2015
The researcher-led workstream welcomes proposals on topics or research questions identified by researchers within the programme’s remit. The HTA can verify this for you if you complete and submit a remit check form. The deadlines for the next two rounds (15/57 Researcher-led Expressions of Interest and 15/58 Researcher-led Evidence Synthesis Full) are both 1pm on Thursday 3 September 2015. Details can be found on the HTA website. Please note that the guidance notes have been updated since the researcher-led call launch in September 2014. Make sure you use the latest version as there have been changes to the advice on technical use of the form and costings for studies.
Pancreatic Cancer Action Early Diagnosis Challenge Award
Applications now open to researchers across the UK.
Awards of up to £40,000 (each) available for research projects with a focus on improving the early diagnosis of pancreatic cancer.
Deadline: 6th July 2015
For more information call 0303 040 1770 or follow the link below:
MRC Biochemical Catalyst: Developmental Pathway Funding Scheme - reminder
The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies. DPFS is an ongoing scheme, with outline deadlines every 4 months. The most recent call opened on 16 June 2015 (deadline for outline proposal: 4pm on 28 July 2015 , panel meets 22-23 September 2015). Please note that full submissions to DPFS are by invitation only; submission to the full call is contingent upon prior submission and shortlisting of an outline proposal. Further details are available from the MRC website.
Pump prime funding for initial feasibility studies
NIHR Enteric HTC aims to identify and address unmet clinical need in the diagnosis and management of disorders of the gastrointestinal tract and bowel function. The HTC seeks new ideas for medical device innovations and offers the opportunity to apply to NIHR Enteric HTC for pump prime funding for initial feasibility studies on potential new medical technologies within the field of digestive diseases and GI surgery.
- Further information[ 33 kb ]
MRC Public Health Intervention Development Scheme (PHIND)
The Public Health Intervention Development scheme (PHIND) is a new MRC funding scheme designed specifically to provide support for early phase development of public health interventions. This rapid response funding scheme is aimed at improving the initial evidence on which the development and evaluation of public health interventions are based. Studies should address an important UK or global public health issue and offer an innovative approach to intervention development or applying an existing intervention in a new setting.
The scheme's remit ranges from primary research developing and designing the intervention to feasibility studies, encompassing:
- developing theory
- modelling process and outcomes
- assessing feasibility
Systematic reviews, meta analyses and pilot studies are outside the remit of the PHIND scheme. Applicants can apply for up to £150K for a maximum of 18 months and the scheme will operate three times a year. For further information, please see the MRC website.